Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant Stereotactic Radiation and Chemotherapy Compared with Upfront Pancreatectomy for Resectable CancerAugust 25, 2016
[Journal of Gastrointestinal Oncology] This research examines outcomes related to the use of neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients.
Research findings reveal the mechanism by which obesity increases inflammation and desmoplasia in the most frequent type of pancreatic cancer, using mouse models and human tissue samples.
Systematic Palliative Care Provides Greater Improvement in Quality of Life for Patients with Pancreatic CancerJuly 29, 2016
Quality of life is significantly improved for patients with pancreatic cancer when systematic palliative care is administered vs on-demand palliative care.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic CancerMay 24, 2016
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
Barriers to Understanding Pancreatic Cancer Can Be Overcome With Improvements to Online Health InformationMay 23, 2016
Available information on pancreatic cancer was written at too high a level and contained inaccuracies regarding alternative therapies, a recent study has shown.
Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapyMay 19, 2016
[Journal of Gastrointestinal Oncology] This research reviews the case history of a patient with stage IVB pancreatic adenocarcinoma initially treated with gemcitabine and erlotinib who stopped therapy after 3 months without achieving a response and was switched to a different and effective combination strategy.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
Lowest accuracy scores for alternative tx websites; websites with higher accuracy more difficult to read
New research indicates a far greater efficacy in pancreatic cancer drug therapy delivered via implantable device than via IV.
An experimental therapy looks to hold promise for tumor control treatment in pancreatic adenocarcinoma.
Two strains of oral bacteria -- P. gingivalis and A. actinomycetemcomitans -- have been linked to higher risk of pancreatic cancer.
An experimental immune therapy can re-educate macrophages to tear down the scaffolding that surrounds and protects pancreatic cancer from chemotherapy.
Adding radiotherapy to chemotherapy and surgery reduced the number of local disease recurrences but did not affect distant recurrences or survival.
Researchers identified four classes of genetic error that triggered pancreatic tumors and classified pancreatic cancer as four separate diseases.
A natural extract from the neem tree of India is found to have potential as a treatment for pancreatic cancer.
An implantable device allows large doses of highly toxic drugs to be delivered directly to pancreatic tumors while reducing exposure to the toxic side effects in the rest of the body.
Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.
The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.
The addition of leucovorin to S-1 significantly improved progression-free survival compared with S-1 alone in patients with advanced pancreatic cancer who were refractory to gemcitabine.
Family members of patients with cancers of unknown primary (CUP) are at higher risk of developing CUP themselves, as well as cancers of the lung, pancreas, and colon and some cancers of the blood.
Blood samples collected from the portal vein can tell physicians far more about a patient's pancreatic cancer than peripheral blood collected from a more easily accessed vein in the arm.
Investigational Drug Is Effective Against Debilitating Adverse Effect of Cancer in Preclinical TrialsDecember 07, 2015
New data describes how an experimental drug can stop the debilitating and life-threatening adverse effect cachexia commonly associated with advanced cancers and restore muscle health.
RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.
Nanoliposomal irinotecan in combination with fluorouracil and folinic acid improves survival in patients with pancreatic ductal adenocarcinoma.
Study findings may explain why chemotherapy drugs such as gemcitabine are not effective for many patients with pancreatic cancer, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth.
A widely available, inexpensive blood test can predict outcomes and guide treatment in pancreatic cancer; however, only 1 in 5 US patients with the disease have the blood test.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients
- PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab
- Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|